PHARMACOLOGICAL SYNERGY BETWEEN HIGH-DOSE ARA-C (HIDAC) AND MITOXANTRONE (MIT) IN MURINE LEUKEMIA L5178Y

被引：0
|
作者：
WANG, LM [1 ]
CAPIZZI, RL [1 ]
CONTENTO, M [1 ]
DIMLING, J [1 ]
机构：
[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,ONCOL RES CTR,WINSTON SALEM,NC 27103
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1986年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：376 / 376
页数：1
相关论文
共 50 条
  • [1] TREATMENT OF MENINGEAL LEUKEMIA WITH HIGH-DOSE ARA-C (HIDAC)
    MORRA, E
    LAZZARINO, M
    INVERARDI, D
    PAGNUCCO, G
    BERNASCONI, C
    LEUKEMIA RESEARCH, 1986, 10 (01) : 113 - 113
  • [2] SCHEDULE-DEPENDENT SYNERGY AND ANTAGONISM BETWEEN ARA-C (AC) AND ASPARAGINASE (A'ASE) ON L5178Y LEUKEMIA
    SCHWARTZ, S
    MORGENSTERN, B
    CAPIZZI, RL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 147 - 147
  • [3] SYNERGY BETWEEN ARA-C AND HIGH-LEVELS OF ARA-U (HIARAU) CONTRIBUTE TO THE THERAPEUTIC EFFICACY OF HIGH-DOSE ARA-C (HIDAC)
    YANG, JL
    CHENG, E
    CAPIZZI, RL
    CHENG, YC
    KUTE, T
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 302 - 302
  • [4] ARA-C SELF-POTENTIATES ITS UPTAKE IN L5178Y LEUKEMIA-CELLS
    WANG, LM
    WHITE, JC
    CAPIZZI, RL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 472 - 472
  • [5] SCHEDULE-DEPENDENT SYNERGY AND ANTAGONISM BETWEEN HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND ASPARAGINASE IN THE L5178Y MURINE LEUKEMIA
    SCHWARTZ, SA
    MORGENSTERN, B
    CAPIZZI, RL
    CANCER RESEARCH, 1982, 42 (06) : 2191 - 2197
  • [6] BIOCHEMICAL AND PHARMACOLOGICAL BASIS OF HIGH-DOSE ARA-C
    SEEBER, S
    ONKOLOGIE, 1985, 8 (01): : 4 - 7
  • [7] PHARMACOKINETICS OF HIGH-DOSE ARA-C (HIDAC) - A PHARMACOLOGIC MEANS FOR SELF POTENTIATION
    CAPIZZI, RL
    YANG, JL
    CHENG, E
    SAHASRABUDHE, D
    TAN, RS
    CHENG, YC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 130 - 130
  • [8] MODULATION OF THE CELLULAR PHARMACOLOGY OF HIGH-DOSE ARA-C (HIDAC) BY ASPARAGINASE (ASNASE)
    WANG, LM
    CAPIZZI, RL
    WHITE, C
    CONTENTO, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 409 - 409
  • [9] A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
    Karanes, C
    Kopecky, KJ
    Head, DR
    Grever, MR
    Hynes, HE
    Kraut, EH
    Vial, RH
    Lichtin, A
    Nand, S
    Samlowski, WE
    Appelbaum, FR
    LEUKEMIA RESEARCH, 1999, 23 (09) : 787 - 794
  • [10] A PHASE-II TRIAL OF HIGH-DOSE ARA-C AND MITOXANTRONE IN ACUTE NONLYMPHOBLASTIC LEUKEMIA (ANLL)
    FUHR, HG
    LINDEMANN, A
    HERRMANN, F
    HIDDEMANN, W
    MERTELSMANN, R
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 121 - 121
12345